The industry-leading AI-powered software for precision-matching patients to clinical trials offers deeper access and visibility into eligible patient populations across 1K+ research facilities in the Deep 6 AI ecosystem

业界领先的人工智能驱动软件，用于将患者与临床试验进行精确匹配，可以更深入地了解Deep 6人工智能生态系统中1K以上研究设施中符合条件的患者人群

PASADENA, Calif., Dec. 6, 2023 /PRNewswire/ -- Deep 6 AI, the leader in AI-powered precision research software which de-risks and accelerates clinical trials for research sites and sponsors, today announced the expansion of its Recruitment Acceleration solution, known for leveraging artificial intelligence (AI) to mine the industry's deepest source of real-time electronic medical record (EMR) data to precisely find patients for trials.

加利福尼亚州帕萨迪纳，2023年12月6日/PRNewswire/-Deep 6 AI是人工智能驱动的精密研究软件的领导者，该软件可以降低风险并加速研究站点和赞助商的临床试验，今天宣布扩展其招聘加速解决方案，以利用人工智能（AI）挖掘行业最深层的实时电子病历（EMR）数据源以精确找到患者进行试验而闻名。

With the expanded solution, life sciences companies can share AI-matched patient cohorts with IRB-approved site staff across the Deep 6 AI ecosystem. This allows sites to identify each patient, validate their eligibility with evidence in the EMR, and track their recruitment statuses faster and more precisely, shortening the time to enrollment..

通过扩展的解决方案，生命科学公司可以在Deep 6 AI生态系统中与IRB批准的现场工作人员共享AI匹配的患者队列。这使网站能够识别每位患者，通过EMR中的证据验证其资格，并更快，更准确地跟踪其招募状态，从而缩短注册时间。。

Deep 6 AI also offers expanded access to all these precision-matched, trial-eligible patients, across all site locations and physicians. The site's research team can easily identify eligible patients treated by physicians other than the principal investigator, validate them, and track referrals inside the EMR.

Deep 6 AI还可以在所有地点和医生中扩大对所有这些精确匹配，符合试验条件的患者的访问。该网站的研究团队可以轻松识别由首席研究者以外的医生治疗的合格患者，对其进行验证，并跟踪EMR内的转诊情况。

This expands the recruitable patient population at any given site and often boosts trial diversity..

这扩大了任何给定地点的可招募患者人数，并经常促进试验多样性。。

'While traditional real-word data (RWD) has become ubiquitous in clinical research, it has many shortcomings that make it insufficient for patient recruitment. By aggregating, normalizing, and tokenizing various types of claims and EMR data types, RWD sacrifices precision, real-time updates, schema flexibility, and easy ties back to real patients,' said Wout Brusselaers, founder and CEO of Deep 6 AI.

“虽然传统的实词数据（RWD）在临床研究中无处不在，但它有许多缺点，不足以招募患者。Deep 6 AI创始人兼首席执行官沃特·布鲁斯莱尔斯（Wout Brusselaers）说，通过聚合、规范化和标记各种类型的声明和EMR数据类型，RWD牺牲了准确性、实时更新、模式灵活性以及与真实患者的轻松联系。

'Deep 6 AI provides a powerful real-time alternative: precision cohorts built from 'real patient data' (RPD), including unstructured physician notes, pathology reports, and genomics data. When life sciences companies plan and execute their trial using the same data as the actual sites recruiting the patients, it de-risks and accelerates accruals and reduces the burden on clinicians and site staff.' .

“Deep 6 AI提供了一个强大的实时替代方案：从“真实患者数据”（RPD）构建的精确队列，包括非结构化的医生笔记，病理报告和基因组学数据。当生命科学公司使用与招募患者的实际地点相同的数据来计划和执行试验时，它可以降低风险并加速累积，减轻临床医生和现场工作人员的负担。”。

Using deep and real-time comprehensive clinical data to identify patient cohorts with unmatched precision lends itself well to observational, real-world evidence (RWE) projects too. With the Deep 6 AI RWE Generation solution, sponsors can leverage its ecosystem for prospective monitoring, registries, and RWE studies or precisely identifying patient charts for review..

使用深度和实时的综合临床数据以无与伦比的精度识别患者队列，也有助于观察性，现实世界证据（RWE）项目。借助Deep 6 AI RWE Generation解决方案，赞助商可以利用其生态系统进行前瞻性监测，注册和RWE研究，或者精确识别患者图表以供审查。。

Deep 6 AI's life sciences solutions also provide access to advanced genomics and diversity, equity, and inclusion (DE&I) insights. Its recently launched genomics module uses AI to find patients with specific genetic markers, enabling precision medicine and cancer researchers to query EMRs for 19,000 genes, multiple mutation types, and over 30,000 locus-specific mutation names.

Deep 6 AI的生命科学解决方案还提供了先进的基因组学和多样性，公平性和包容性（DE＆I）见解。其最近推出的基因组学模块使用人工智能来寻找具有特定遗传标记的患者，使精准医学和癌症研究人员能够查询EMR中的19000个基因，多种突变类型和30000多个基因座特异性突变名称。

Additionally, its solutions provide race and ethnicity data at the site, cohort, and patient levels to help organizations develop a Race and Ethnicity Diversity Plan and meet diverse enrollment goals faster. .

此外，其解决方案还提供了站点、队列和患者级别的种族和民族数据，以帮助组织制定种族和民族多样性计划，并更快地实现多样化的入学目标。。

Life sciences companies can meet with Deep 6 AI at the 42nd JPM Healthcare Conference 2024 in San Francisco, California and at the SCOPE Summit 2024 in Orlando, Florida. Contact the team to schedule a meeting.

生命科学公司可以在2024年加利福尼亚州旧金山举行的第42届JPM医疗保健会议和2024年佛罗里达州奥兰多举行的SCOPE峰会上与Deep 6 AI会面。联系团队安排会议。

About Deep 6 AI Deep 6 AI is the leader in clinical trial acceleration software, enabling healthcare organizations and life sciences companies to de-risk trial design, improve feasibility, and accelerate recruitment. Its AI-powered software mines structured and unstructured electronic medical record data to precisely match patients to clinical trials in real time across its ecosystem of 1K+ research facilities, including 18 academic medical centers, 11 NCI-Designated Cancer Centers, and 3 NCI Community Oncology Research Programs.

关于Deep 6 AI Deep 6 AI是临床试验加速软件的领导者，使医疗保健组织和生命科学公司能够降低试验设计风险，提高可行性并加速招聘。其人工智能驱动的软件挖掘结构化和非结构化电子病历数据，以便在其1K+研究设施的生态系统中实时精确地将患者与临床试验相匹配，包括18个学术医疗中心，11个NCI指定的癌症中心和3个NCI社区肿瘤学研究项目。

Visit deep6.ai to learn more. .

访问deep6.ai了解更多信息。。

Media contact: Laurie Thackeray VP, Marketing, Deep 6 AILaurie.thackeray@deep6.ai(919) 619-3105

媒体联系人：Laurie Thackray深度6营销副总裁ailaurie.thackeray@deep6.ai（919）619-3105

SOURCE Deep 6 AI

源深度6 AI